Re: Exon 53 - two clinical trials in the U.S. both with morpholinos
Yup, once that PPMO is proved to work as expected the floodgates should open. I guess that'll be the job of the new CEO. Maybe this Meeker guy from Genzyme or Kress ... but at the moment the only thing I've got to wonder about is this odd "notion" that I just read a few minutes ago from a report on a "talk with management" about pipeline: ..."Dosing in the PPMO program is on track to
start by year-end in healthy volunteers, and will move to DMD patients in
2018."
Does Kaye really think he's going to find some healthy volunteers out there who want to get DMD for a while? Maybe if the price is right?......?!